Evotec AG (NASDAQ:EVO) Given Average Recommendation of “Hold” by Brokerages

Evotec AG (NASDAQ:EVO) has received an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.00.

Several analysts have recently issued reports on EVO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Berenberg Bank began coverage on shares of Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating on the stock.

Hedge Funds Weigh In On Evotec

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP acquired a new stake in shares of Evotec in the fourth quarter worth approximately $40,000. Valeo Financial Advisors LLC purchased a new stake in shares of Evotec during the second quarter worth approximately $43,000. BNP Paribas Financial Markets raised its stake in Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in Evotec in the 3rd quarter valued at $53,000. Finally, Bank of America Corp DE lifted its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Trading Down 1.7%

Shares of NASDAQ EVO opened at $2.34 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03. The firm has a fifty day moving average of $3.26 and a 200 day moving average of $3.39. Evotec has a one year low of $2.31 and a one year high of $4.80.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.